Febrile neutropenia (FN) rates in metastatic hormone sensitive prostate cancer: the role of antibiotics as primary prophylaxis-Reference-Cited by-同舟云学术

Febrile neutropenia (FN) rates in metastatic hormone sensitive prostate cancer: the role of antibiotics as primary prophylaxis

Published:2020-07-24 Issue:1 Volume:24 Page:166-168
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

Pemberton Lara^ORCID,Ng Kenrick^ORCID,McGovern Ursula,Macdonald Alan,Barot Hasti,Galazi Myria,Wilson Peter,Wells Paula,Linch Mark,Alifrangis Constantine,Shamash Jonathan

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Urology,Oncology

Link

http://www.nature.com/articles/s41391-020-0261-z.pdf

Reference10 articles.

1. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737–46.

2. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163–77.

3. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.

4. Rulach RJ, McKay S, Neilson S, White L, Wallace J, Carruthers R, et al. Real-world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer. BJU Int. 2018;121:268–74.

5. Tsao CK, Galsky MD, Oh WK. Docetaxel for metastatic hormone-sensitive prostate cancer: urgent need to minimize the risk of neutropenic fever. Eur Urol. 2016;70:707–8.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neutropenic sepsis rates in patients receiving bleomycin, etoposide and cisplatin chemotherapy using olanzapine and reduced doses of dexamethasone compared to a standard antiemetic regimen;BJU International;2020-08-17